Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab

Files in this item

This item appears in the following Collection(s)

Search DSpace



Browse

My Account

Statistics